All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Prazer Therapeutics Inc. has identified mitogen-activated protein kinase 14 (MAPK14) inhibitors reported to be useful for the treatment of inflammatory disorders.
